Minerva Surgical Inc (UTRS) fair value: what the stock is really worth
We calculate from audited financials what Minerva Surgical Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Jul 31, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch Minerva Surgical Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Minerva Surgical, Inc. provides a suite of devices to treat the root causes of abnormal uterine bleeding in the United States.
Show more
Minerva Surgical, Inc. provides a suite of devices to treat the root causes of abnormal uterine bleeding in the United States. The company provides Minerva Endometrial Ablation System, a technology that uses three methods of tissue ablation; Symphion System that is designed for fluid management, direct intrauterine pressure monitoring, and bladeless resection work; and Genesys HTA, an endometrial ablation device for the treatment of a wider range of uterine cavities. It also offers Resectr, a tissue resection device to diagnose and treat polyps; and HERizon electronic disposable hysteroscope, image processor, Hysto-Kit, and endoscopic accessories that helps gynecologists to evaluate abnormal uterine bleeding and provide care. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Stock analysis
Minerva Surgical Inc (UTRS) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, so the stock looks roughly fairly valued today (gap 0.0%).
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Minerva Surgical Inc reported revenue of $51.7M in FY2023 versus $26.0M in FY2019, a compound +18.7%/yr. Reported net income was −$33.5M in FY2023.
Key figures
Market cap $887 · EPS (TTM) $−0.7600 · Net margin −64.7% · Return on equity −160% · Return on assets (EBIT) −32.2% · Operating margin −51.0% · Revenue (TTM) $51.7M · Revenue growth (YoY) −4.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).
What moves the price
The share trades about 90% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 0%, UTRS screens richer than that median.
Fair Value models
Bear $0.0001Fair Value $0.0001Bull $0.0001
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.29/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+2.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
’19
’20
’21
’22
’23
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−75.5% (2019) → −56.6% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2022 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 350 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Minerva Surgical Inc (UTRS) overvalued or undervalued?
As of Jul 31, 2026, our model estimates a fair value of $0.0001 versus a price of $0.0001, about +0% upside (fairly valued).
What is the fair value of UTRS?
Our model-based fair value for Minerva Surgical Inc is $0.0001 (as of Jul 31, 2026), built from audited fundamentals. The current price: $0.0001.
What is the quality score of UTRS?
Minerva Surgical Inc has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Minerva Surgical Inc (UTRS)?
Our model-based price target is the fair value of $0.0001 (as of Jul 31, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Minerva Surgical Inc stock forecast for 2026?
Our models put fair value at $0.0001, about +0% upside versus a price of $0.0001 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of Minerva Surgical Inc (UTRS)?
Minerva Surgical Inc reported trailing-twelve-month revenue of about $51.7M (latest available figure, as of Jul 31, 2026).
What is the intrinsic value of Minerva Surgical Inc (UTRS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Minerva Surgical Inc it is $0.0001 per share (as of Jul 31, 2026), against a price of $0.0001. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Minerva Surgical Inc stock overvalued or undervalued in 2026?
As of Jul 31, 2026, UTRS trades below its calculated fair value: price $0.0001, fair value $0.0001, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of UTRS?
No. The price is what the market pays today ($0.0001); the fair value is what the company's own numbers justify ($0.0001). For Minerva Surgical Inc the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Minerva Surgical Inc worth?
The market values Minerva Surgical Inc at about $887 (market capitalisation, as of Jul 31, 2026). Per share that is $0.0001; our models calculate a fair value of $0.0001 per share.
How solid is the balance sheet of Minerva Surgical Inc (UTRS)?
Balance-sheet figures for Minerva Surgical Inc (as of Jul 31, 2026): return on equity −160.1%, debt of 2.18 per unit of equity. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is UTRS from its 52-week high?
Minerva Surgical Inc trades at $0.0001, about 90% below its 52-week high of $0.0010 and at the low of $0.0001 (as of Sep 29, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0001 is for.
Which stocks are comparable to Minerva Surgical Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Minerva Surgical Inc stock attractive at the current price?
The data as of Jul 31, 2026: price $0.0001, calculated fair value $0.0001 (+0%), Quality Score 27/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of UTRS calculated?
We run Minerva Surgical Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0001, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Minerva Surgical Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Minerva Surgical Inc (UTRS)?
The closing price on Sep 29, 2026 was $0.0001. Our model-based fair value is $0.0001, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Minerva Surgical Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Minerva Surgical Inc
How large is the market capitalisation of Minerva Surgical Inc (UTRS)?
The market capitalisation of Minerva Surgical Inc is $887. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Minerva Surgical Inc (UTRS)?
Earnings per share at Minerva Surgical Inc are $−0.7600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Minerva Surgical Inc (UTRS)?
The net margin of Minerva Surgical Inc is −64.7% (fiscal year 2023). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Minerva Surgical Inc (UTRS)?
The return on equity (ROE) of Minerva Surgical Inc is −160% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Minerva Surgical Inc (UTRS)?
On an EBIT basis the return on assets of Minerva Surgical Inc is −32.2% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Minerva Surgical Inc (UTRS)?
The operating margin of Minerva Surgical Inc is −51.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Minerva Surgical Inc (UTRS)?
Revenue at Minerva Surgical Inc is growing −4.9% versus a year earlier (3y avg +11.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Minerva Surgical Inc (UTRS) generate?
The free cash flow of Minerva Surgical Inc is −$38.8M (fiscal year 2023). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Minerva Surgical Inc (UTRS) carry?
The net debt of Minerva Surgical Inc is $32.7M (fiscal year 2022). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Minerva Surgical Inc in the live analysis
One click puts Minerva Surgical Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Jul 31, 2026